The ARC™ proprietary technology offers directed and targeted antibody removal
drawing on all the strengths of current antibody removal techniques while avoiding
the major weaknesses.
This specifically allows for:
drawing on all the strengths of current antibody removal techniques while avoiding
the major weaknesses.
This specifically allows for:
- • Better patient care
- • More transplantation surgeries by:
- • making a living donor, HLA antibody-incompatible transplant easier and safer,
- • performing living donor transplants currently prohibited in highly sensitized patients because of their antibody levels,
- • extending transplantation into areas currently not feasible, such as deceased donor transplants across antibody barriers, and
- • investigating the role of selective antibody removal in chronic
antibody-mediated rejection to prolong the life of the donor organ after
transplantation
- • Lower medical insurance impact from long-term care of wait-listed patients
- • Improved quality of life post-transplant by enhancing the effectiveness of
traditional long-term anti-rejection therapy without creating secondary health conditions.
Prototype and Pre-clinical ARC™ studies have Achieved Proof-of-Concept.
Pre-clinical trials have demonstrated that a 65-mg ARC™ column can deplete the anti-HLA antibody
concentration in a patient volume of plasma from a prohibitively high concentration down to a clinically
acceptable level to allow a patient to receive a previously unacceptable donor organ, leaving
concentrations of other antibodies untouched.
Recent Comments